2023年全球结核病报告（英）-75页_2mb

The 2023 Global Tuberculosis Report underscores a dual challenge: signs of recovery post-pandemic but a widening gap from ambitious TB targets. In 2022, global efforts rebounded significantly, reversing pandemic-related decline, with case notifications reaching their highest level since 1995 and TB incidence and mortality showing near-complete recovery. However, decades-long trends of declining TB incidence and mortality remain off-track.

Key setbacks include missed global targets from the 2018 UN High-Level Meeting, such as treatment coverage (70% vs. 80% pre-pandemic), funding (US$5.8 billion, a 30% decline from 2019), and preventive treatment (15.5 million served, 52% of targets).

The TB epidemic remains severe, with 30 high-burden countries accounting for 87% of the global TB cases. While treatment success rates for drug-susceptible TB reached 88%, drug-resistant TB (MDR/RR-TB) saw only 43% of cases receiving treatment, highlighting gaps in diagnostics and funding. Catastrophic costs—exceeding 20% of household income—burdened 87% of TB patients in LMICs.

The COVID-19 pandemic exacerbated TB gaps, with COVID-related disruptions causing an estimated 475,000 excess TB deaths in 2020–2022. Preventive measures, including multisectoral accountability frameworks and equitable access to testing/financing, are critical to achieving the End TB Strategy milestones. New tools like shorter drug regimens and vaccines offer hope, yet increased funding (toward US$22 billion by 2027) and strengthened public health infrastructure are essential.

The roadmap forward emphasizes rapid rollout of new technologies, enhanced community engagement, and renewed political commitment to accelerate towards a TB-free future.